Form 4: Olema Pharmaceuticals CEO Sells Shares to Cover Tax Obligations After Performance-Based Stock Units Vest

Olema Pharmaceuticals CEO, Sean Bohen, sold shares to cover tax obligations following the vesting of performance-based restricted stock units.

Summary

• Olema Pharmaceuticals CEO, Sean Bohen, had performance restricted stock units (PRSUs) vest on December 9, 2024, after the Compensation Committee certified the achievement of performance milestones.
• These PRSUs were initially granted on November 11, 2022, for 315,000 shares, with 35% vesting on November 20, 2023, and the remaining 65% vesting on December 9, 2024.
• To cover tax withholding obligations associated with the vesting, Mr. Bohen sold a total of 109,902 shares of common stock in multiple transactions.
• The sales occurred automatically as 'sell to cover' transactions and were not discretionary trades by Mr. Bohen.
• The weighted average sale price for the first transaction on December 10, 2024, was $9.37, with prices ranging from $8.87 to $9.70.
• The weighted average sale price for the second transaction on December 11, 2024, was $8.66, with prices ranging from $8.22 to $9.21.
• The weighted average sale price for the third transaction on December 11, 2024, was $9.39, with prices ranging from $9.31 to $9.74.
• Mr. Bohen also acquired 1,489 shares under the company's Employee Stock Purchase Plan on June 30, 2024.

Sentiment

Score: 6

Explanation: The document describes a routine transaction related to executive compensation. While the sale of shares might cause some concern, it is a standard practice for tax purposes and does not indicate a negative outlook for the company.

Positives

• The vesting of the PRSUs indicates that the company met certain performance criteria set by the Compensation Committee.
• The automatic sale of shares to cover tax obligations is a standard practice and does not indicate a lack of confidence in the company by the CEO.

Negatives

• The sale of shares by the CEO, even for tax purposes, could be perceived negatively by some investors.

Risks

• The market may react negatively to the CEO selling shares, even if it is for tax purposes.
• There is a risk that the stock price could be affected by the sale of a large number of shares.

Management Comments

• The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This type of transaction is common for executives who receive stock-based compensation, particularly when performance-based units vest. It is a standard practice to sell shares to cover the tax obligations associated with the vesting.

Comparison to Industry Standards

• The vesting of performance-based stock units and subsequent sale to cover tax obligations is a common practice among publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Many companies use similar 'sell to cover' mechanisms to manage tax liabilities for their executives.
• The specific vesting criteria and performance milestones are unique to Olema Pharmaceuticals, but the overall structure is consistent with industry norms.

Stakeholder Impact

• Shareholders may have a neutral to slightly negative reaction to the sale of shares by the CEO, even if it is for tax purposes.
• Employees may view the vesting of PRSUs as a positive sign of the company's performance.

Key Dates

Keywords

Olema Pharmaceuticals, Sean Bohen, Performance Restricted Stock Units, PRSU, Stock Sale, Tax Withholding, Vesting, Compensation Committee, Employee Stock Purchase Plan